Prevention of adhesions

• US 6,841,153 B1
• Filed: 10/01/1999
• Issued: 01/11/2005
• Est. Priority Date: 10/02/1998
• Status: Expired due to Fees

• Current Assignee: Genzyme Corporation (Sanofi ), University of Florida (State University System of Florida), Wayne State University
• Original Assignee: Genzyme Corporation (Sanofi ), University of Florida (State University System of Florida), Wayne State University
• Inventors: Burns, James, Diamond, Michael P., Holmdahl, Lena E., Chegini, Nasser
• Primary Examiner(s): Nolan, Patrick J.
• Assistant Examiner(s): HADDAD, MAHER M
• Application Number:
  US09/787,144
• Time in Patent Office: 1,929 Days
• Field of Search: 424/146.1, 424/145.1, 424/178.1, 530/357.5, 530/385.76, 530/389.2, 530/388.24
• US Class Current: 424/145.1
• CPC Class Codes: C07K 16/38 against protease inhibitors of peptide structure

Abstract

Methods for the prevention of adhesion formation involve the administration of therapeutic formulations to a patient which include antibodies to TIMP-1 or TIMP-1 antisense oligonucleotides. The formulations can also include suitable carriers, such as a hyaluronic acid matrix, for optimal administration. The treatment procedure can be initiated and monitored by a diagnostic procedure which involves the detection of elevated levels of TIMP-1 in a patient.

Claims

1. A method for reducing surgical adhesion formation, comprising administering a therapeutic formulation comprising TIMP-1 antibodies, or Fab fragments thereof, to a patient at risk of surgical adhesion formation, wherein the therapeutic formulation is administered in an amount effective to reduce the local level of TIMP-1 and surgical adhesion formation.

2. The method of claim 1, wherein the therapeutic formulation comprises TIMP-1 antibodies, and wherein the TIMP-1 antibodies are monoclonal antibodies.

3. The method of claim 1, wherein the therapeutic formulation comprises TIMP-1 antibodies, and wherein the TIMP-1 antibodies are polyclonal antibodies.

4. The method of claim 1, wherein the therapeutic formulation further comprises a suitable carrier.

5. The method of claim 4, wherein the carrier is hyaluronic acid.

6. The method of claim 1, wherein the surgical adhesion is a peritoneal adhesion.

7. The method of claim 1, wherein the surgical adhesion is a surgical adhesion of intra-peritoneal tissue selected from the group consisting of parietal peritoneum, uterus, fallopian tube, ovary, bowel, and omentum.